超声刺激微泡增强检查点抑制剂治疗
本研究在结直肠癌细胞系CT26模型中探讨抗血管超声刺激微泡(USMB)联合抗PD-1检查点抑制剂治疗的疗效。纵向实验显示USMB联合抗PD-1治疗较单药治疗显著增强肿瘤生长抑制并延长动物生存,但流式细胞术和ELISPOT数据未明确支持T细胞依赖机制,增强的具体机制尚待确立。
要点
- USMB联合抗PD-1较单药显著增强肿瘤生长抑制和动物生存。
- 流式细胞术和ELISPOT未明确支持T细胞依赖机制。
- USMB增强检查点抑制剂疗效的具体机制尚待确立。
核心结论
- 抗血管USMB能够增强检查点抑制剂治疗的抗肿瘤效果,但增强的具体机制尚待确立。
研究设计与样本
- 使用结直肠癌细胞系CT26进行纵向肿瘤生长研究和急性实验,通过流式细胞术和ELISPOT分析评估超声诱导的抗肿瘤免疫反应。
局限性
- 流式细胞术和ELISPOT数据未明确支持T细胞依赖机制。
- 增强的具体机制尚待确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Checkpoint inhibitor (CI) immunotherapy is playing an increasingly prominent role in the treatment of cancer but is effective and durable in only a subset of patients. There are concerted efforts to improve CI therapy through the use of multiple CIs or use of CIs in combination with other anti-cancer agents. Here we investigate the use of "anti-vascular" ultrasound-stimulated microbubble (USMB) treatments in combination with anti-PD-1 CI therapy. The colorectal cancer cell line CT26 was used to conduct longitudinal growth studies along with acute experiments to assess ultrasound-induced anti-tumor immune responses using flow cytometry and enzyme-linked immunospot (ELISPOT) analysis. Longitudinal experiments indicated that USMB + anti-PD-1 treatments significantly enhanced tumor growth inhibition and animal survival relative to monotherapies. Flow cytometry and ELISPOT data did not clearly support a T cell-dependent mechanism for the enhancement. Therefore, the results indicate the ability of anti-vascular USMBs to increase the anti-tumor effects of CI therapy; the specific mechanisms of enhancement remain to be established.
引用
- Bulner S, Prodeus A, Gariepy J, et al. Enhancing Checkpoint Inhibitor Therapy with Ultrasound Stimulated Microbubbles. Ultrasound Med Biol. 2018. PMID: 30447880. doi:10.1016/j.ultrasmedbio.2018.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。